Zomedica presents Truforma BAW research

Zomedica announced the presentation of research highlighting the improved diagnostic capabilities of the Truforma Bulk Acoustic Wave, or BAW, platform when evaluating cats for thyroid disease compared to widely utilized chemiluminescent immunoassay, or CLIA, platforms.The presentation, “Evaluation of a Feline-Optimized TSH Assay in Cats with Hyperthyroidism and with Non-Thyroidal Illness,” will be given by Camille Brassard, DVM, IPSAV, at the American College of Veterinary Internal Medicine Forum being held in Minneapolis, Minnesota. The Truforma diagnostic platform utilizes unique proprietary BAW technology that provides highly precise and sensitive measurements at levels that other optical-based diagnostic methods do not achieve. Currently, Truforma in-clinic diagnostic systems provide accurate, rapid, and reliable diagnostic results to veterinarians, assisting in their diagnosis and treatment of complex thyroid and adrenal conditions, canine non-infectious gastrointestinal disease, and equine Cushing’s disease – all providing reference lab quality with point-of-care convenience. Zomedica anticipates introducing additional veterinary assays to the market, further enabling reference lab quality with point-of-care convenience. DeMonaco recently initiated two additional studies in collaboration with Zomedica, further highlighting the need to utilize the BAW platform for properly diagnosing and monitoring hyperthyroid cats. These studies include: TSH in cats with illness and as predictor of survivability and TSH as a predictor of outcome in hyperthyroid cats treated with radioiodine therapy.